Nelarabine Completed Phase 2 Trials for Malignant Lymphomas / Leukemias Treatment

Indications	Status	Purpose	Phase
DBCOND0046362 (Malignant Lymphomas) DBCOND0035632 (Leukemias)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
https://clinicaltrials.gov/ct2/show/	506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Nelarabine (DB01280)